- Home
- SDRL vs EWTX Comparison
SDRL vs EWTX Comparison
Compare SDRL & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDRL
- EWTX
- Stock Information
- Founded
- SDRL 2005
- EWTX 2017
- Country
- SDRL Bermuda
- EWTX United States
- Employees
- SDRL N/A
- EWTX N/A
- Industry
- SDRL Oil & Gas Production
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- SDRL Energy
- EWTX Health Care
- Exchange
- SDRL Nasdaq
- EWTX Nasdaq
- Market Cap
- SDRL 1.5B
- EWTX 1.2B
- IPO Year
- SDRL N/A
- EWTX 2021
- Fundamental
- Price
- SDRL $28.01
- EWTX $14.30
- Analyst Decision
- SDRL Strong Buy
- EWTX Buy
- Analyst Count
- SDRL 5
- EWTX 8
- Target Price
- SDRL $56.50
- EWTX $39.63
- AVG Volume (30 Days)
- SDRL 1.1M
- EWTX 932.9K
- Earning Date
- SDRL 08-04-2025
- EWTX 08-07-2025
- Dividend Yield
- SDRL N/A
- EWTX N/A
- EPS Growth
- SDRL 37.29
- EWTX N/A
- EPS
- SDRL 5.56
- EWTX N/A
- Revenue
- SDRL $1,288,000,000.00
- EWTX N/A
- Revenue This Year
- SDRL $3.80
- EWTX N/A
- Revenue Next Year
- SDRL $5.71
- EWTX N/A
- P/E Ratio
- SDRL $5.12
- EWTX N/A
- Revenue Growth
- SDRL N/A
- EWTX N/A
- 52 Week Low
- SDRL $17.74
- EWTX $10.60
- 52 Week High
- SDRL $56.46
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- SDRL 65.00
- EWTX 41.90
- Support Level
- SDRL $27.40
- EWTX $14.87
- Resistance Level
- SDRL $29.41
- EWTX $15.68
- Average True Range (ATR)
- SDRL 1.23
- EWTX 0.67
- MACD
- SDRL 0.21
- EWTX -0.02
- Stochastic Oscillator
- SDRL 77.15
- EWTX 15.25
About SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.